Figure 13.

HER-3 vaccine antibodies used in combination with HER-1, HER-2 or IGF-1R vaccine antibodies results in increased levels of ADCC. Various cancer cells (target cells) were seeded and incubated in the presence of human PBMCs at different effector: target cell ratios (100:1, 20:1, 4:1). Cells were then treated for one hour with antibodies/combinations of antibodies prior to cell lysis. The Acella-tox kit (Cell Technology) was used to measure the relative amount of ADCC. Results display the % lysis of treatment groups when compared to 100% target cell lysis. Normal rabbit IgG (Pierce) was used as a negative control. Results display averages for two independent experiments with triplicate samples (n = 3). Error bars represent SD of the average. Combination treatment showed significant induction of ADCC in all three cell lines used with a significant value of *p < 0.05 for BT-474 cells, **p < 0.005 for BxPC-3 cells and **p = 0.037 for JIMT-1 cells. Single treatment with the HER-1 and HER-3 in BxPC-3 cells or IGF-IR inhibitors in JIMT-1 cells showed a lesser significant value (*p < 0.05).